Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) EPS (Basic) (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed EPS (Basic) for 16 consecutive years, with $2.33 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 235.47% to $2.33 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.36 through Dec 2025, up 4992.31% year-over-year, with the annual reading at $6.44 for FY2025, 3027.27% up from the prior year.
  • EPS (Basic) hit $2.33 in Q4 2025 for Ligand Pharmaceuticals, down from $5.99 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $5.99 in Q3 2025 to a low of -$2.88 in Q2 2024.
  • Historically, EPS (Basic) has averaged $0.67 across 5 years, with a median of $0.41 in 2022.
  • Biggest five-year swings in EPS (Basic): tumbled 2315.38% in 2024 and later surged 1635.9% in 2025.
  • Year by year, EPS (Basic) stood at -$0.19 in 2021, then crashed by 352.63% to -$0.86 in 2022, then soared by 210.47% to $0.95 in 2023, then tumbled by 281.05% to -$1.72 in 2024, then soared by 235.47% to $2.33 in 2025.
  • Business Quant data shows EPS (Basic) for LGNDZ at $2.33 in Q4 2025, $5.99 in Q3 2025, and $0.25 in Q2 2025.